Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances of immunotherapy for biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Review of Gastroenterology & Hepatology (2020) Vol. 15, Iss. 5, pp. 527-536
Closed Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancers (2021) Vol. 13, Iss. 3, pp. 558-558
Open Access | Times Cited: 230
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 549-555
Closed Access | Times Cited: 111
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 4, pp. 343-350
Closed Access | Times Cited: 101
Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100328-100328
Open Access | Times Cited: 88
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100354-100354
Open Access | Times Cited: 88
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
Alessandro Rizzo, Vincenzo Dadduzio, Angela Dalia Ricci, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 4, pp. 371-378
Closed Access | Times Cited: 85
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!”
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100335-100335
Open Access | Times Cited: 80
Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Immunotherapy (2021) Vol. 13, Iss. 8, pp. 637-644
Closed Access | Times Cited: 80
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer
Alessandro Rizzo, Giovanni Brandi
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 5, pp. 547-554
Closed Access | Times Cited: 78
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100337-100337
Open Access | Times Cited: 76
Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach
Felix Krenzien, Nora Nevermann, Alina Krombholz, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 362-362
Open Access | Times Cited: 54
Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials
Md. Musavvir Mahmud, Nikhil Pandey, Jeffrey A. Winkles, et al.
Nano Today (2024) Vol. 56, pp. 102314-102314
Closed Access | Times Cited: 12
IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma
Haijiao Yan, Qian Deng, Yu Meng, et al.
Cancer Biotherapy and Radiopharmaceuticals (2025)
Closed Access | Times Cited: 1
SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma
Weiqiang You, Jia Ke, Yufeng Chen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 34
The epidemiological trends of biliary tract cancers in the United States of America
Jiang Yong, Liyong Jiang, Feiyu Li, et al.
BMC Gastroenterology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 32
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
Stephen P. Hack, Wendy Verret, Sohail Mulla, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 34
Immunotherapy in Advanced Biliary Tract Cancers
Alice Boilève, Marc Hilmi, Cristina Smolenschi, et al.
Cancers (2021) Vol. 13, Iss. 7, pp. 1569-1569
Open Access | Times Cited: 33
Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
Sandra Kang, Bassel F. El‐Rayes, Mehmet Akce
Cancers (2022) Vol. 14, Iss. 7, pp. 1748-1748
Open Access | Times Cited: 24
Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors
Hao Sun, Li Chen, Rong Huang, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 22
New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma
Etsushi Kawamura, Tsutomu Matsubara, Norifumi Kawada
Cancers (2023) Vol. 15, Iss. 15, pp. 3993-3993
Open Access | Times Cited: 15
Cross-Talk Between Tumor Cells and Stellate Cells Promotes Oncolytic VSV Activity in Intrahepatic Cholangiocarcinoma
Victoria Neumeyer, P. Chavan, Katja Steiger, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 514-514
Open Access
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma
Younghoon Kim, Jaewon Song, Namkyoung Kim, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Comprehensive clinical and genetic characterization of hyperprogressive biliary tract cancer during PD-1 blockade monotherapy: case report and literature review
Kangxin Wang, Xudong Yang, Fen Guo, et al.
BMC Medical Genomics (2025) Vol. 18, Iss. 1
Open Access
Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers
Ruyin Chen, Dandan Zheng, Qiong Li, et al.
Cancer Letters (2022) Vol. 546, pp. 215853-215853
Closed Access | Times Cited: 21
Page 1 - Next Page

Scroll to top